February 26, 2019
Debiopharm set to test its antibiotic to treat severe bone and joint infections in phase 2 clinical trial
Debiopharm International, a Swiss-based global biopharmaceutical company, has started testing its antibiotic afabicin (Debio 1450) for the treatment of staphylococcal bone and joint infections in a clinical phase II study.